自体角膜缘干细胞移植治疗翼状胬肉60例

目的观察自体角膜缘干细胞移植对翼状胬肉疗效的影响。方法在手术显微镜下,采用自体角膜缘干细胞移植治疗初发性和复发性翼状胬肉60例(65眼),术后随访观察6个月～4年。结果54例(58眼)痊愈,6例(7眼)复发,术后复发率为12.07%。结论自体角膜缘干细胞移植治疗翼状胬肉,有助于角膜、结膜的重建,阻止新生血管及结膜上皮侵入角膜,有效抑制了胬肉的复发,是治疗翼状胬肉的理想手术方法。

人羊膜移植联合自体角膜缘干细胞移植治疗中重度眼部碱烧伤

目的 观察人羊膜移植联合自角膜缘干细胞移植治疗中重度眼部碱烧伤的临床效果。方法 对 8眼中重度眼部碱烧伤早期进行人羊膜移植联合自体角膜缘干细胞移植。结果 8眼中 ,7眼眼表面重建成功 ,4眼角膜透明 ,3眼角膜半透明 ,仅 1眼发生轻度睑球粘连。结论 人羊膜移植联合自体角膜缘干细胞移植治疗中重度眼部碱烧伤。对于重建眼表面 ,提高视功能 ,早期应用疗效较好。

极小胚胎样干细胞的研究现状和眼科临床意义

极小胚胎样干细胞(very small embryonic-like stem cells,VSELs)是美国路易斯维尔大学Kucia研究小组从小鼠骨髓和人脐带血中分离出一种具有类似胚胎干细胞生物特性的多潜能成体干细胞。与胚胎干细胞相似的外表——细胞形态及表面标志、以及相似的内在——多分化潜能决定了VSELs一出现就被细胞替代疗法视为最有潜力的种子细胞,本文就VSELs的研究历程及在眼科干细胞治疗视网膜退行性疾病中的临床意义作一综述。

Umbilical cord mesenchymal stem cell transplantation for the treatment of Duchenne muscular dystrophy

Due to their relative abundance,stable biological properties and excellent reproductive activity,umbilical cord mesenchymal stem cells have previously been utilized for the treatment of Duchenne muscular dystrophy,which is a muscular atrophy disease.Three patients who were clinically and pathologically diagnosed with Duchenne muscular dystrophy were transplanted with umbilical cord mesenchymal stem cells by intravenous infusion,in combination with multi-point intramuscular injection.They were followed up for 12 months after cell transplantation.Results showed that clinical symptoms significantly improved,daily living activity and muscle strength were enhanced,the sero-enzyme,electromyogram,and MRI scans showed improvement,and dystrophin was expressed in the muscle cell membrane.Hematoxylin-eosin staining of a muscle biopsy revealed that muscle fibers were well arranged,fibrous degeneration was alleviated,and fat infiltration was improved.These pieces of evidence suggest that umbilical cord mesenchymal stem cell transplantation can be considered as a new regimen for Duchenne muscular dystrophy.

Generation of Transgene-free Induced Pluripotent Stem Cells with Non-viral Methods

Induced pluripotent stem （iPS） cells were originally generated from mouse fibroblasts by enforced expression of Yamanaka factors （Oct3/4, Sox2, Klf4, and c-Myc）. The technique was quickly re- produced with human fibroblasts or mesenchymal stem cells. Although having been showed therapeutic po- tential in animal models of sickle ceil anemia and Parkinson＇s disease, iPS cells generated by viral methods do not suit all the clinical applications. Various non-viral methods have appeared in recent years for application of iPS cells in cell transplantation therapy. These methods mainly include DNA vector-based approaches, transfection of mRNA, and transduction of reprogramming proteins. This review summarized these non-viral methods and compare the advantages, disadvantages, efficiency, and safety of these methods.

Progress in treatment of peripheral T-cell lymphoma with hematopoietic stem cell transplantation

The general chemotherapy for Peripheral T-cell lymphoma(PTCL) featuring an active invasion has less curative effect and worse prognosis in comparison with that for B-cell non-Hodgkin's lymphoma(NHL).Studies in recent years suggest that hematopoietic stem cell transplantation(HSCT) has better curative effect on the PTCL;however,it is significant to do more studies on some aspects such as the methodology,punctuality,preconditioning,and pretreatment intensity of the transplantation,which are crucial to the curative effect.

Progress in the treatment of myocardial infarction with stem cells transplantation

Embryonic stem cells and adult stem cells derives from bone marrow, muscule, liver, skin, nerve, adiposes and other tissues or organs are pluripotent. Embryonic stem cells in vitro can differentiate into derivatives of all three embryonic germ layers when transferred to an in vitro environment, and have the ability to form any fully differentiated cells of the body. A series of remarkable studies suggested that adult stem cells undergo novel patterns of development named as transdifferentiation. All of them can be induced into cardiomyocytes in a certain condition and used to treat myocardial infarction. In this review, progress in the treatment of myocardial infarction with stem cells transplantation is summarized.

Reduced-intensity conditioning allogeneic stem cell transplantation in malignant lymphoma: current status

stem cell transplantation （allo-SCT） is a potential cure for patients with malignant lymphoma that is based on the graft-versus-lymphoma （GVL） effect. Myeloablative conditioning allo-SCT is associated with high mortality and morbidity, particularly in patients older than 45 years, heavily pretreated patients （prior hematopoietic stem cell transplantation or more than two lines of conventional chemotherapy） or patients affected by other comorbidities. Therefore, conventional allo-SCT is restricted to younger patients （〈50 to 55 years） in good physical condition. Over the last decade, allo-SCT with reduced-intensity conditioning （RIC-allo-SCT） has been increasingly used to treat patients with lymphoma. This treatment is associated with lower toxicity and substantial decrease in the incidence of transplant- related mortality, and has the potential to lead to long-term remissions. Therefore, patients who are not suitable to undergo conventional allo-SCT can benefit from the potentially curative GVL effects of allo-SCT. Although RIC-allo-SCT has improved the survival of lymphoma patients, high post-transplant relapse rates or disease progression mainly results in treatment failure. Thus, further improvement is clearly needed. The role and timing of RIC-allo-SCT in the treatment of lymphoma remains unclear. Therefore, more prospective studies should clarify the effectiveness of this method. In this article, we review the recent literature on RIC-alIo-SCT as a treatment for major lymphoma subtypes. Areas that require further investigation in the context of clinical trials are also highlighted.

Timing of transplantation of autologous bone marrow derived mesenchymal stem cells for treating myocardial infarction

It is still unclear whether the timing of intracoronary stem cell therapy affects the therapeutic response in patients with myocardial infarction.The natural course of healing the infarction and the presence of putative homing signals within the damaged myocardium appear to favor cell engraftment during the transendothelial passage in the early days after reperfusion.However,the adverse inflammatory environment,with its high oxidative stress,might be deleterious if cells are administered too early after reperfusion.Here we highlight several aspects of the timing of intracoronary stem cell therapy.Our results showed that transplantation of bone marrow mesenchymal stem cells at 2 4 weeks after myocardial infarction is more favorable for reduction of the scar area,inhibition of left ventricular remodeling,and recovery of heart function.Coronary injection of autologous bone marrow mesenchymal stem cells at 2 4 weeks after acute myocardial infarction is safe and does not increase the incidence of complications.

Treatment of multiple sclerosis by transplantation of neural stem cells derived from induced pluripotent stem cells

Multiple sclerosis(MS) is an autoimmune disease of the central nervous system(CNS), with focal T lymphocytic infiltration and damage of myelin and axons. The underlying mechanism of pathogenesis remains unclear and there are currently no effective treatments. The development of neural stem cell(NSC) transplantation provides a promising strategy to treat neurodegenerative disease. However, the limited availability of NSCs prevents their application in neural disease therapy. In this study, we generated NSCs from induced pluripotent stem cells(iPSCs) and transplanted these cells into mice with experimental autoimmune encephalomyelitis(EAE), a model of MS. The results showed that transplantation of iPSC-derived NSCs dramatically reduced T cell infiltration and ameliorated white matter damage in the treated EAE mice. Correspondingly, the disease symptom score was greatly decreased, and motor ability was dramatically rescued in the iPSC-NSC-treated EAE mice, indicating the effectiveness of using iPSC-NSCs to treat MS. Our study provides pre-clinical evidence to support the feasibility of treating MS by transplantation of iPSC-derived NSCs.

Potential advantages of a combination of Chinese Medicine and bone marrow mesenchymal stem cell transplantation for removing blood stasis and stimulating neogenesis during ischemic stroke treatment

Combined treatment of ischemic stroke with Chinese medicine and exogenous bone marrow mesenchymal stem cell(BMSC) transplantation may improve the removal of blood stasis and stimulation of neogenesis.Chinese medicines that remove blood stasis not only promote blood circulation but also calm the endopathic wind,remove heat,resolve phlegm,remove toxic substances and strengthen body resistance.The medicinal targeting effect of Chinese medicine can promote the homing of BMSCs,and the synergistic therapeutic effects of drugs can contribute to BMSC differentiation.As such,exogenous BMSC transplantation has potential advantages for neogenesis.Chinese medicines and exogenous BMSCs provide complementary functions for the removal of blood stasis and stimulation of neogenesis.Therefore,a combination of Chinese medicine and transplantation of exogenous BMSCs may be particularly suited to ischemic stroke treatment.